Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort

被引：0
|
作者：
Kallweit, U. [1 ]
Jelcic, I. [1 ]
Braun, N. [1 ]
Fischer, H. [1 ]
Zoerner, B. [1 ]
Schreiner, B. [1 ]
Sokolov, A. [1 ]
Martin, R. [1 ]
Weller, M. [1 ]
Linnebank, M. [1 ]
机构：
[1] Univ Zurich Hosp, CH-8091 Zurich, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P950
引用
收藏
页码：S429 / S429
页数：1
相关论文
共 50 条
  • [21] Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
    Havrdova, Eva
    Galetta, Steven
    Hutchinson, Michael
    Stefoski, Dusan
    Bates, David
    Polman, Chris H.
    O'Connor, Paul W.
    Giovannoni, Gavin
    Phillips, J. Theodore
    Lublin, Fred D.
    Pace, Amy
    Kim, Richard
    Hyde, Robert
    LANCET NEUROLOGY, 2009, 8 (03): : 254 - 260
  • [22] No evidence of disease activity status among patients with relapsing-remitting multiple sclerosis on long-term natalizumab treatment: data from a real-world cohort in the Czech Republic
    Horakova, D.
    Vaneckova, M.
    Krasensky, J.
    Seidl, Z.
    van Pesch, V.
    van Wijmeersch, B.
    Ribbens, A.
    van Hecke, W.
    Freudensprung, U.
    Hyde, R.
    Ho, P. -R.
    Kokic, M.
    Uher, T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 409 - 410
  • [23] Efficacy/safety profile of cladribine in an italian real-life cohort of relapsing remitting multiple sclerosis patients
    Zanetta, C.
    Sangalli, F.
    Guerrieri, S.
    Filippi, M.
    Montini, F.
    Moiola, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 325 - 325
  • [24] Real-world safety and effectiveness of natalizumab treatment in patients with relapsing-remitting multiple sclerosis: data from an Irish registry
    McGuigan, C.
    Kinirons, P.
    Ryan, A.
    Moore, H.
    Murphy, S. M.
    Hennessy, M.
    Gibson, B.
    Hayden, B.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 299 - 300
  • [25] Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis
    Novakova, Lenka
    Axelsson, Markus
    Khademi, Mohsen
    Zetterberg, Henrik
    Blennow, Kaj
    Malmestrom, Clas
    Piehl, Fredrik
    Olsson, Tomas
    Lycke, Jan
    JOURNAL OF NEUROCHEMISTRY, 2017, 141 (02) : 296 - 304
  • [26] Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
    Planas, Raquel
    Martin, Roland
    Sospedra, Mireia
    PATIENT-RELATED OUTCOME MEASURES, 2014, 5 : 25 - 33
  • [27] The association between disease activity and disability progression in patients with relapsing-remitting multiple sclerosis
    Spelman, T.
    Geale, K.
    Anell, B.
    Hillert, J.
    Wong, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 127 - 128
  • [28] Sustained efficacy in relapsing remitting multiple sclerosis following switch to placebo treatment from cladribine tablets in patients with high disease activity at baseline
    Vermersch, P.
    Giovannoni, G.
    Soelberg-Sorensen, P.
    Keller, B.
    Jack, D.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 268 - 269
  • [29] Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: a real-life observational study
    Moreau, A.
    Kolitsi, I.
    Kremer, L.
    Fleury, M. -C.
    Collongues, N.
    De Seze, J.
    Bigaut, K.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 640 - 640
  • [30] Efficacy and Safety Profile of Cladribine Tablets in an Italian Real-Life Cohort of Relapsing-Remitting Multiple Sclerosis Patients: A Monocentric Longitudinal Observational Study
    Zanetta, Chiara
    Rocca, Maria
    Meani, Alessandro
    Preziosa, Paolo
    Martinelli, Vittorio
    Ferre, Laura
    Moiola, Lucia
    Filippi, Massimo
    NEUROLOGY, 2023, 100 (17)
12345